Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 36 of 232 for:    clindamycin

Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03883269
Recruitment Status : Recruiting
First Posted : March 20, 2019
Last Update Posted : March 20, 2019
Sponsor:
Collaborator:
Maruho Co., Ltd.
Information provided by (Responsible Party):
Centre for Human Drug Research, Netherlands

Brief Summary:
The combined bacteriostatic and immunomodulatory effects of erythromycin and clindamycin will be explored. Treatment effects will be extensively characterized by conventional methods including lesion counts, global assessment scales and visual grading as well as state-of-the-art methodology, including multi-modal photo analysis, perfusion by laser speckle contrast imaging, analysis of local skin surface, biopsy biomarkers and skin microbiota. This extensive response profiling, combined with the mechanistic insights from concurrent in vitro and in vivo studies in healthy volunteer challenges, will increase the understanding of erythromycin's and clindamycin's effects in acne vulgaris.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: Erythromycin 4% topical gel formulation Drug: Clindamycin 1% topical lotion formulation Drug: 70% topical ethanol solution Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A randomized, open-label, placebo-controlled, evaluator-blinded study.
Masking: Single (Outcomes Assessor)
Masking Description: Evaluator-blinded
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Evaluator-blinded, Study to Assess the Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Patients With Inflammatory Facial Acne
Actual Study Start Date : March 20, 2018
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Experimental: Erythromycin 4%
Erythromycin 4% topical gel formulation, BID, 4 weeks
Drug: Erythromycin 4% topical gel formulation
Erythromycin 4% topical gel formulation, BID, 4 weeks

Experimental: Clindamycin 1%
Clindamycin 1% topical lotion formulation, BID, 4 weeks
Drug: Clindamycin 1% topical lotion formulation
Clindamycin 1% topical lotion formulation, BID, 4 weeks

Placebo Comparator: ethanol solution
70% topical ethanol solution, BID, 4 weeks
Drug: 70% topical ethanol solution
70% topical ethanol solution, BID, 4 weeks




Primary Outcome Measures :
  1. Efficacy endpoint 1 - Change in lesion count [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]
    The inflammatory lesions include papules pustules and nodules/cysts. At screening and every study visit, the evaluator will count the inflammatory lesions separately by area on the face (forehead, right cheek, left cheek, chin and nose). All lesion counts during the treatment and follow-up period will be performed by a treatment-blinded evaluator

  2. Efficacy endpoint 2 - Change in investigator Global Assessment acne (IGA) [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]
    Acne severity will be assessed at screening and every study visit by the Investigator Global Assessment for facial acne (clear, almost clear, mild, moderate, severe, very severe). This will be done by a treatment blinded evaluator.

  3. Change in Patient Reported Outcome (PRO) [ Time Frame: Day 0 and day 28 ]
    Pre-dose and at EOT patients will be asked how they would rate their acne that day using the subjective Patient Global Assessment (clear, almost clear, mild, moderate, severe, very severe)

  4. Pharmacodynamic endpoints 1 - Change in Standardized facial photography by Canfield Visia and via selfie app [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]
    A standardized set of 3 facial photos (front, left, right) will be taken every study visit by Canfield Visia CR. Furthermore, patients will take daily selfies with a validated mobile app.

  5. Pharmacodynamic endpoints 2 - Change in Sebum measurements by Sebumeter® [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]
    Sebum excretion will be measured every study visit by Sebumeter®. The measurement will be repeated for 3 times and the average will be used for the analysis.

  6. Pharmacodynamic endpoints 3 - Change in Perfusion by Laser Speckle Contrast Imaging (LSCI) [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]

    Cutaneous microcirculation will be assessed using the laser speckle imager (LSCI; PeriCam PSI System, Perimed Jäfälla, Sweden). Measurements have to be performed in a temperature controlled room with a temperature around 22°C. The subject has to get accommodated to the room temperature for a minimum of 15 minutes prior to testing. After this, the speckle assessments can commence. Briefly, the subject will be resting for at least ten minutes before any measurements take place. A suitable area of the face will be identified. This area will be illuminated' by the laser and the response signal will be captured.

    If no suitable area can be identified, the measurement will not be performed and data will be entered as missing.


  7. Pharmacodynamic endpoints 4 - Change in Morphology by Optical Coherence Tomography (OCT) [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]
    Skin morphology will be assessed by optical coherence tomography at every study visit. Optical coherence tomography uses reflected light returning from skin tissue to create an image of the skin and 2 mm below the skin. The visualization can be done because different skin structures reflect light in a different way and can therefore be distinguished. Optical coherence tomography is similar to ultrasound however instead of sound it uses light refraction to visualize tissue.

  8. Pharmacodynamic endpoints 5 - Change in Local skin biopsy biomarkers [ Time Frame: Day 0 and day 28 ]
    Two-millimetre punch biopsies are taken at day 0 and day 28 from a papule or pustule. Moreover, at day 0 a biopsy will be taken from nonlesional non-facial skin (upper back) as healthy control. The biopsies will be placed in RNAlater medium directly after harvest of the biopsy and stored at 4°C. Biomarker sequencing will be performed by RNA extraction and quantitative PCR will be performed for a subset of immunomodulatory biomarkers (including but not limited to IL-1b, IL-1a, TNF-a IL-6, IL-12, IL-8, IL-10, IL-17, IFN-g).

  9. Pharmacodynamic endpoints 6 - Change in Local skin surface biomarkers by TAP [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]

    Skin biomarkers will be measured pre-dose and after 7, 14, 21, 28, and 42 days by TAP (FibroTx, Estonia). TAP consists of a multiplex capture-antibody micro-array that is supported by a dermal adhesive bandage for fixture to skin. When TAP is applied to skin and left on for 20 minutes, the antibodies printed on the micro-array capture biomarkers from skin through immune recognition.

    Biomarkers (IL-1a, IL-1b, TNF-a, IL-8, IL-6, IL-17) captured from skin by TAP are qualitatively and quantitatively analyzed by spot-ELISA by a specific TAP analyzer.


  10. Pharmacodynamic endpoints 7 - Change in skin microbiota [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]
    The skin swab will be placed in a 2 ml lysis tube containing DNA/RNA shield to stabilize and preserve the DNA. The DNA extraction will be performed using adapted DNA extraction method based on the Zymo Research fecal DNA extraction methodology. The microbiome will be analyzed according to 16S rRNA gene sampling

  11. Pharmacodynamic endpoints 8 - Change over time in p. acnes cultures [ Time Frame: Day 0, day 7, day 14, day 21, day 28 and day 42 ]

    Swabs of predefined lesional (papule of pustule) and non-lesional skin will be taken with a sterile cotton swab. Colony numbers (colony forming units - CFU) and minimal inhibitory concentrations (MIC) will be reported. In addition, swabs of other lesions (i.e. nodules or scars) may be taken if applicable.

    Moreover, in order to study P. acnes in the pilosebaceous unit a comedo extraction will be performed and the sebum will be cultured for P. acnes. Comedo extraction will be performed if applicable (i.e. if the patient has comedones).


  12. Pharmacodynamic endpoints 9 - Change over time in faecal microbiota [ Time Frame: before day 0 and after day 28 ]
    Faecal samples will be collected at home. Subjects will use a 'faeces catcher' in their toilet and afterwards use a cotton swab to transfer a scoop of faeces to a 2 ml lysis tube (REF ZY-R1103, Zymo Research) containing DNA/RNA shield to stabilize and preserve the DNA.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male and female subjects, 18 to 45 years of age. The health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease other than AV following a detailed medical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, virology and urinalysis;
  2. Mild to moderate inflammatory acne vulgaris on the face, ≥5 inflammatory lesions (papules and/or pustules), present at screening and baseline visit
  3. A maximum of 5 nodules present at screening and baseline visit
  4. Inflammatory acne present for at least 6 months
  5. Fitzpatrick skin type I-II (Caucasian)
  6. Able and willing to give written informed consent and to comply with the study restrictions.
  7. Willing to comply with 2x2mm facial skin punch biopsies

Exclusion Criteria:

  1. Severe acne where systemic treatment is needed
  2. Use of any topical (anti-acne) medication (prescription or OTC) within 2 weeks prior to baseline
  3. Use of any oral/systemic treatment for acne, including oral antibiotics, excluding OAC, within 4 weeks prior to baseline
  4. Use of systemic isotretinoin within 6 months prior to baseline
  5. History of pathological scar formation (keloid, hypertrophic scar)
  6. Known hypersensitivity to erythromycin or clindamycin, drugs of the same class, or any of their excipients.
  7. Known contact dermatitis reaction to any product
  8. Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of enrollment.
  9. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year.
  10. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening
  11. Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03883269


Contacts
Layout table for location contacts
Contact: Robert Rissmann, PharmD, PhD +31 71 5246 400 clintrials@chdr.nl
Contact: Diana Noort +31 71 5246 400 clintrials@chdr.nl

Locations
Layout table for location information
Netherlands
Centre for Human Drug Research Recruiting
Leiden, Netherlands, 2333 CL
Contact: Robert Rissmann, PharmD, PhD    +31 71 5246 400    clintrials@chdr.nl   
Contact: Diana Noort    +31 71 5246 400    clintrials@chdr.nl   
Sponsors and Collaborators
Centre for Human Drug Research, Netherlands
Maruho Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Robert Rissmann, PharmD, PhD CHDR

Layout table for additonal information
Responsible Party: Centre for Human Drug Research, Netherlands
ClinicalTrials.gov Identifier: NCT03883269     History of Changes
Other Study ID Numbers: CHDR1732
First Posted: March 20, 2019    Key Record Dates
Last Update Posted: March 20, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Ethanol
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Pharmaceutical Solutions
Anti-Inflammatory Agents
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Bacterial Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents